Abstract: A method for reducing or eliminating tyramine interference from amphetamine and methamphetamine immunoassays, comprising treating the sample with aqueous tyramine oxidase for a time and at a temperature and pH sufficient to deaminate any tyramine present in the sample, is provided.

Abstract: Galactopyranoside derivative compounds for use as substrates for hydrolysis by enzymes with .beta.-galactosidase activity are provided. The concentration of the reaction products can be measured by spectroscopy. The compounds find particular use in diagnostic assays for detection of analyte.

Abstract: Galactopyranoside derivative compounds for use as substrates for hydrolysis by enzymes with .beta.-galactosidase activity are provided. The concentration of the reaction products can be measured by spectroscopy. The compounds find particular use in diagnostic assays for detection of analyte.

Abstract: An automated microscope-slide-staining apparatus, having a supporting framework; an arm moveable in three dimensions attached to the framework; apparatus for moving the arm; a hollow tip head located on the arm; apparatus for alternatively supplying positive or negative gas pressure to the hollow tip head; a removable wash/blow tip having an exit slit, the wash/blow tip being adapted to be removably attached to the hollow tip head by a preselected movement of the arm; a wash/blow tip holder at a first fixed location on the framework; a reagent application tip holder at a second fixed location on the framework for holding a reagent application tip, the reagent application tip being adapted to be removably attached to the hollow tip head by a preselected movement of the arm; a reagent container holder at a third fixed location on the framework; a microscope slide holder at a fourth fixed location on the framework, the microscope slide holder being adapted to removably contain the microscope slide; and control a

Abstract: Compounds are evaluated for their binding to naturally occurring receptors, by employing the natural ligand conjugated to an enzyme donor fragment of .beta.-galactosidase for competing with the sample compound for the natural acceptor binding site or in the absence of competition where the sample compound binds to an allosteric site. By adding the enzyme acceptor fragment of the .beta.-galactosidase and substrate, the binding affinity of the sample compound may be evaluated as a measure of agonist or antagonist capability.

Abstract: Provided by the present invention is a novel cytokine, IL-9, an approximately 144 amino acid protein, characterized by an apparent molecular weight of between 20 to 30 kD and having biological activity in an MO7E cell assay. The cytokine can be used, inter alia, as a mitogen, as an antigen, and to regulate hematopoiesis.

Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.

Abstract: This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.

Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.

Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.

Abstract: Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the polypeptide sequence, and preferably being further modified by deletion of certain N-terminal amino acids. Such CAVs may be additionally modified by the coupling of sulfhydryl reactive compounds to the introduced cysteine residue(s) without loss of bioactivity to produce selected homogeneously modified IL-3 and improved pharmaceutical compositions containing the same.

Abstract: Homogeneous K-FGF and a process for its production are provided. Also provided are pharmaceutical compositions for use in treating soft tissue injuries and musculo-skeletal disorders in mammals and methods of treatment. The purification of the bacterially produced K-FGF comprises reduction of a salt solution containing K-FGF to effect the precipitation of the product.

Abstract: A composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene/M-CSF receptor protein are provided. The composition involves a M-CSF polypeptide cross-linked to a cytotoxic agent capable of crossing into the cytoplasm of the cell bearing the receptor and killing the cell.

Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.

Abstract: A mixed composition polyhedral inclusion body (PIB) is provided which contains a mixture of nucleocapsids of at least two genetically distinct baculoviruses. At least one of the baculoviruses is genetically engineered to contain at least one heterologous gene. Followed ingestion of the mixed composition PIB by an insect host, a mixed viral infection ensues in the insect permitting the production therein of additional copies of the mixed composition PIB and the production of a heterologous protein encoded by the heterologous gene present in at least one of the baculoviruses.

Abstract: An improved method for inducing leukocytosis in a primate is disclosed. The method includes co-administering IL-3 in conjunction with GM-CSF, such that the leukocyte count in the primate is synergistically raised.

Abstract: An improved bacterial host cell useful for the inducible production and secretion in high yields of a heterologous protein is provided which contains a gene encoding the heterologous protein operatively linked to a secretory leader-encoding sequence and to an expression control sequence which contains a promoter region; and a second DNA sequence encoding a repressor capable of binding to said promoter region. The cell contains at least a mutation in the repressor binding region of the promoter or a mutation in the promoter binding region of the repressor-encoding sequence; or mutations in both regions. These mutation(s) lower the frequency of transcriptional induction by the promoter from the observed with the wild-type promoter and/or repressor-encoding sequence, resulting in higher yields of secreted heterologous protein.

Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.

Abstract: Methods are presented for lowering levels of lipoprotein cholesterol, serum cholesterol and other lipids comprising the administration of M-CSF or GM-CSF.

Abstract: This invention provides genes encoding aspartate beta decarboxylase, vectors containing the genes, microbial host cells transformed with the vectors, and the use of such transformed host cells and compositions derived therefrom to produce L-alanine and certain derivatives thereof.